After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Andrew Dunn

Senior Biopharma Correspondent

Simon Kohl turned an internship at Google DeepMind into a key role in building AlphaFold2, the Nobel Prize-winning AI model that predicts the structure of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

NIH’s funding cut plan poses challenges for researchers despite court halt

AbbVie pens another T cell engager deal, this time with Xilio

AnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis

Biogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet

Novo's weight loss drug helps curb some drinking habits, small study shows

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Af­ter help­ing build Al­phaFold, a 34-year-old first-time CEO launch­es his own AI biotech with $50M

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

NIH’s fund­ing cut plan pos­es chal­lenges for re­searchers de­spite court halt

Ab­b­Vie pens an­oth­er T cell en­gager deal, this time with Xilio

Anap­tys­Bio gets a mid-stage win for PD-1 drug in rheuma­toid arthri­tis

Bio­gen down­plays ca­pac­i­ty for M&A; Roche’s SMA drug is ap­proved as a tablet

Novo's weight loss drug helps curb some drink­ing habits, small study shows

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

NIH’s funding cut plan poses challenges for researchers despite court halt

AbbVie pens another T cell engager deal, this time with Xilio

AnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis

Biogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet

Novo's weight loss drug helps curb some drinking habits, small study shows

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers